Kimberly Maersk-Moller Sells 2,111 Shares of MiMedx Group, Inc. (NASDAQ:MDXG) Stock

MiMedx Group, Inc. (NASDAQ:MDXG) insider Kimberly Maersk-Moller sold 2,111 shares of MiMedx Group stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $8.40, for a total value of $17,732.40. Following the completion of the sale, the insider now directly owns 265,271 shares of the company’s stock, valued at approximately $2,228,276.40. This trade represents a 0.79 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

MiMedx Group Stock Down 1.1 %

MDXG stock opened at $8.00 on Friday. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $1.18 billion, a PE ratio of 14.55 and a beta of 1.97. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14. The stock has a 50-day simple moving average of $8.63 and a two-hundred day simple moving average of $7.75.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.07. The business had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. On average, equities analysts predict that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on MDXG. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price objective on shares of MiMedx Group in a report on Thursday, February 27th. StockNews.com lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, MiMedx Group currently has a consensus rating of “Buy” and an average price target of $12.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. IMG Wealth Management Inc. purchased a new position in MiMedx Group during the 4th quarter valued at about $28,000. Virtus Fund Advisers LLC purchased a new position in MiMedx Group during the 4th quarter valued at about $35,000. Van ECK Associates Corp purchased a new position in MiMedx Group during the 4th quarter valued at about $40,000. Point72 DIFC Ltd grew its holdings in shares of MiMedx Group by 127.6% during the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock worth $45,000 after purchasing an additional 4,275 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock worth $63,000 after purchasing an additional 2,837 shares during the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.